The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
lexicon sells rights to cardio drug to viatris amid restructuring efforts
Lexicon Pharmaceuticals has sold the rights to its cardio drug, sotagliflozin, to Viatris for $25 million upfront, with potential milestone payments of up to $200 million. This move comes as Lexicon restructures and aims to expand into Type 1 diabetes, with an FDA advisory panel set to review the drug's use in this area on October 31. The approval could unlock a $400 million U.S. market for the drug, which is currently marketed as Inpefa for heart failure and related conditions.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.